Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Posted: March 8, 2025 at 2:45 am
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.
Posted in Global News Feed
Comments Off on Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Posted: March 8, 2025 at 2:45 am
SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its intention to file a Form 25 Notification of Delisting with the Securities and Exchange Commission on March 17, 2025, which will remove Oncternal's securities from listing and registration on Nasdaq, and to subsequently deregister with the Securities and Exchange Commission (“SEC”). Nasdaq previously suspended the trading of Oncternal’s common stock on December 3, 2024 and notified Oncternal that a Form 25 would be filed. However, as Nasdaq has not yet made the filing, Oncternal is doing so voluntarily to permit Oncternal to file a Form 15 to deregister with the SEC.
Posted in Global News Feed
Comments Off on Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Posted: March 8, 2025 at 2:45 am
WARREN, N.J., March 07, 2025 (GLOBE NEWSWIRE) -- Mittul Mehta, Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, recently joined industry leaders at Proskauer’s AI discussion panel, "Attuned AI: Shaping AI to Empower Your Industry," held on March 6, 2025, in New York City.
See the rest here:
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Posted in Global News Feed
Comments Off on Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Posted: March 8, 2025 at 2:45 am
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and full year 2024 ending December 31, 2024 on Thursday, March 13, 2025 after the close of the US market.
The rest is here:
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Posted in Global News Feed
Comments Off on Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Posted: March 8, 2025 at 2:45 am
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2024.
See the rest here:
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Posted in Global News Feed
Comments Off on UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
RAPT Therapeutics to Participate in Upcoming Investor Conferences
Posted: March 8, 2025 at 2:45 am
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March:
Read more here:
RAPT Therapeutics to Participate in Upcoming Investor Conferences
Posted in Global News Feed
Comments Off on RAPT Therapeutics to Participate in Upcoming Investor Conferences
Curia Announces Strategic Refinancing to Support Continued Growth
Posted: March 8, 2025 at 2:45 am
ALBANY, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced it has refinanced its senior secured credit facilities.
View post:
Curia Announces Strategic Refinancing to Support Continued Growth
Posted in Global News Feed
Comments Off on Curia Announces Strategic Refinancing to Support Continued Growth
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Posted: March 8, 2025 at 2:45 am
ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024.
Go here to read the rest:
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Posted in Global News Feed
Comments Off on Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
Posted: March 8, 2025 at 2:45 am
TORONTO, March 07, 2025 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the “Offering”). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2024.
Visit link:
Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
Posted in Global News Feed
Comments Off on Blueberries Medical Announces C$1 Million Non-Brokered Private Placement
Better Choice Company to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 27th at 4:30 p.m. ET
Posted: March 8, 2025 at 2:45 am
TAMPA, Fla., March 07, 2025 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced it will host a conference call and webcast on Thursday, March 27, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year 2024 and provide a business update.
Here is the original post:
Better Choice Company to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 27th at 4:30 p.m. ET
Posted in Global News Feed
Comments Off on Better Choice Company to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 27th at 4:30 p.m. ET
